The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus
Open accessAbstract
In type-2 diabetes, the overall incretin effect is reduced. The present investigation was designed to compare insulinotropic actions of exogenous incretin hormones (gastric inhibitory peptide [GIP] and glucagon-like peptide 1 [GLP-1] [7-36 amide]) in nine type-2 diabetic patients (fasting plasma glucose 7.8 mmol/liter; hemoglobin A1c 6.3 +/- 0.6%) and in nine age- and weight-matched normal subjects. Synthetic human GIP (0.8 and 2.4 pmol/kg.min over 1 h each), GLP-1 [7-36 amide] (0.4 and 1.2 pmol/kg.min over 1 h each), and placebo were administered under hyperglycemic clamp conditions (8.75 mmol/liter) in separate experiments. Plasma GIP and GLP-1 [7-36 amide] concentrations (radioimmunoassay) were comparable to those after oral glucose with the low, and clearly supraphysiological with the high infusion rates. Both GIP and GLP-1 [7-36 amide] dose-dependently augmented insulin secretion (insulin, C-peptide) in both groups (P < 0.05). With GIP, the maximum effect in type-2 diabetic patients was significantly lower (by 54%; P < 0.05) than in normal subjects. With GLP-1 [7-36 amide] type-2 diabetic patients reached 71% of the increments in C-peptide of normal subjects (difference not significant). Glucagon was lowered during hyperglycemic clamps in normal subjects, but not in type-2 diabetic patients, and further by GLP-1 [7-36 amide] in both groups (P < 0.05), but not by GIP. In conclusion, in mild type-2 diabetes, GLP-1 [7-36 amide], in contrast to GIP, retains much of its insulinotropic activity. It also lowers glucagon concentrations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In individuals with T2DM, there is a decrease in the incretin effect which primarily attributed to the diminished effects of gastric inhibitory polypeptide (GIP).9”
From GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review (2024) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Among the two incretin hormones, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), the latter has been established as having therapeutic potential for reducing elevated plasma glucose (1, 2) and body weight (3), while the former has been unable to either stimulate insulin secretion (1) or lower plasma glucose effectively in type 2 diabetes (T2D) (4).”
From The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications (2026) · cites this paper as [1]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Despite the slight differences based on the subject cohort and the duration of treatment, this magnitude of weight loss was largely consistent with the SURPASS trials132-140.”
From Transforming obesity: The advancement of multi-receptor drugs (2024) · cites this paper as [137]
Experimental — accuracy not yet measuredIn the citing paper
“which is not observed in the set of T2D where the endocrine pancreas ceases responsiveness to GIP but remains responsive to GLP-1, explaining the reduced/absent incretin effect of GIP in T2D [22,23].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [23]
In the citing paper
“However, GIP action is lost in T2D and even infusions of GIP that result in supraphysiological concentrations fail to elicit a significant insulin secretory response in T2D patients.160”
From A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives (2021) · cites this paper as [160]
In the citing paper
“in type 2 diabetes, a markedly attenuated insulinotropic action of GIP (66) and, in some cases, attenuated secretion of GLP-1 (67), contribute to an impairment of postprandial insulin secretion, so that the latter is insufficient to maintain euglycaemia.”
From Gut mechanisms linking intestinal sweet sensing to glycemic control (2018) · cites this paper as [66]
In the citing paper
“In the setting of GIP/GLP-1 receptor agonist (dual agonism), GLP-1 quells the potential glucagon-stimulatory effects of GIP (64) and also (re)sensitizes beta cells to GIP's incretin effects (57), all while potentially enhancing GIP's beneficial effects on weight regulation mechanisms.”
From New Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics (2023) · cites this paper as [57]
In the citing paper
“It remained in the shadow of GLP-1, partly because GIP-stimulated insulin secretion is significantly blunted in individuals with T2D (56); notably, responsiveness can be restored by mitigating hyperglycemia (57).”
From New Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics (2023) · cites this paper as [57]
In the citing paper
“GIP has been found to stimulate glucagon secretion, particularly at lower glucose values [14], whereas GLP-1 suppresses glucagon release and, consequently, reduces hepatic glucose production [15].”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [15]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glucose clamp technique: a method for quantifying insulin secretion and resistance.
DeFronzo, R. A., Tobin, J. D., & Andres, R. (1979) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1979.237.3.e214 · Cited by 7,425
The Triumvirate: β-Cell, Muscle, Liver: A Collusion Responsible for NIDDM
DeFronzo, R. A. (1988) · Diabetes · doi:10.2337/diab.37.6.667 · Cited by 2,456
Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928
Reduced incretin effect in Type 2 (non-insulin dependent) diabetes
Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia · doi:10.1007/bf02427280 · Cited by 1,307
Self-citationPlasma Insulin Responses to Oral and Intravenous Glucose: Studies in Normal and Diabetic Subjects*
Perley, M. J., & Kipnis, D. M. (1967) · Journal of Clinical Investigation · doi:10.1172/jci105685 · Cited by 917
Mojsov, S., Weir, G. C., & Habener, J. F. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112855 · Cited by 889
NAUCK, M. A., HOMBERGER, E., SIEGEL, E. G., ALLEN, R. C., EATON, R. P., EBERT, R., & CREUTZFELDT, W. (1986) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-63-2-492 · Cited by 874
Self-citationGutniak, M., Ørkov, C., Holst, J. J., Ahrén, B., & Efendić, S. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205143262003 · Cited by 868
Self-citationSTIMULATION OF INSULIN SECRETION BY GASTRIC INHIBITORY POLYPEPTIDE IN MAN. 1
Dupre, J., Ross, S. A., Watson, D., & Brown, J. C. (1973) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-37-5-826 · Cited by 860
Creutzfeldt, W. (1979) · Diabetologia · doi:10.1007/bf01225454 · Cited by 731
Self-citation
Research works printed but not linked: 1
- [45]45. Creutzfeldt, W., and U. R. Folsch. 1983. Delaying Absorption as a Thera- peutic Principle in Metabolic Disease. Georg-Thieme-Verlag, Stuttgart.
Cited by
Sorted by citations
Items 101–200 of 1,003
Nauck, M. A. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2010.11.002 · Cited by 298
Self-citationChu, Z., Jones, R. M., He, H., Carroll, C., Gutierrez, V., Lucman, A., Moloney, M. K., Gao, H., Mondala, H., Bagnol, D., et al. (2007) · Endocrinology · doi:10.1210/en.2006-1608 · Cited by 295
Glucose-Sensing in Glucagon-Like Peptide-1-Secreting Cells
Reimann, F. M., & Gribble, F. M. (2002) · Diabetes · doi:10.2337/diabetes.51.9.2757 · Cited by 293
The structure and function of the glucagon‐like peptide‐1 receptor and its ligands
Donnelly, D. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01687.x · Cited by 292
Kopp, K. O., Glotfelty, E. J., Li, Y., & Greig, N. H. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106550 · Cited by 298
Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure
Hansotia, T., Maida, A., Flock, G., Yamada, Y., Tsukiyama, K., Seino, Y., & Drucker, D. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci25483 · Cited by 290
Glucagon-like peptide 1(GLP-1) in biology and pathology
Meier, J. J., & Nauck, M. A. (2005) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.538 · Cited by 288
Self-citationMin, T., & Bain, S. C. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00981-0 · Cited by 314
Regulation of Glucose Homeostasis by GLP-1
Nadkarni, P., Chepurny, O. G., & Holz, G. G. (2014) · Progress in Molecular Biology and Translational Science · doi:10.1016/b978-0-12-800101-1.00002-8 · Cited by 287
Metabolic Effects of Bariatric Surgery in Patients With Moderate Obesity and Type 2 Diabetes
Kashyap, S. R., Bhatt, D. L., Wolski, K., Watanabe, R. M., Abdul‐Ghani, M. A., Abood, B., Pothier, C. E., Brethauer, S. A., Nissen, S. E., Gupta, M. K., et al. (2013) · Diabetes Care · doi:10.2337/dc12-1596 · Cited by 286
Assessment of Pancreatic β-Cell Function: Review of Methods and Clinical Applications
Cersósimo, E., Solis‐Herrera, C., TRAUTMANN, M. E., Malloy, J. L., & Triplitt, C. L. (2014) · Current Diabetes Reviews · doi:10.2174/1573399810666140214093600 · Cited by 288
Coffee Consumption and Risk of Type 2 Diabetes Mellitus Among Middle-aged Finnish Men and Women
Tuomilehto, J. O. (2004) · JAMA · doi:10.1001/jama.291.10.1213 · Cited by 281
D'Alessio, D., Kahn, S., Leusner, C. R., & Ensinck, J. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117225 · Cited by 309
Loss of Incretin Effect Is a Specific, Important, and Early Characteristic of Type 2 Diabetes
Holst, J. J., Knop, F. K., Vilsbøll, T., Krarup, T., & Madsbad, S. (2011) · Diabetes Care · doi:10.2337/dc11-s227 · Cited by 289
Self-citationInter-organ cross-talk in metabolic syndrome
Priest, C., & Tontonoz, P. (2019) · Nature Metabolism · doi:10.1038/s42255-019-0145-5 · Cited by 279
Alpha cell function in health and disease: influence of glucagon-like peptide-1
Dunning, B. E., Foley, J. E., & Åhrén, B. (2005) · Diabetologia · doi:10.1007/s00125-005-1878-0 · Cited by 276
Shu, L., Matveyenko, A. V., Kerr-Conte, J. A., Cho, J., McIntosh, C. H. S., & Maedler, K. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp178 · Cited by 269
Holst, J. J. (1997) · Annual Review of Physiology · doi:10.1146/annurev.physiol.59.1.257 · Cited by 271
Self-citationExendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans
Schirra, J., Sturm, K., Leicht, P., Arnold, R., Göke, B., & Katschinski, M. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1349 · Cited by 265
GIF biology and fat metabolism
Yip, R. G. C., & Wolfe, M. M. (1999) · Life Sciences · doi:10.1016/s0024-3205(99)00314-8 · Cited by 266
GPR119, a novel G protein‐coupled receptor target for the treatment of type 2 diabetes and obesity
Overton, H. A., Fyfe, M. C. T., & Reynet, C. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707529 · Cited by 264
Transgenic pigs as models for translational biomedical research
Aigner, B., Renner, S., Keßler, B., Klymiuk, N., Kurome, M., Wünsch, A., & Wolf, E. (2010) · Journal of Molecular Medicine · doi:10.1007/s00109-010-0610-9 · Cited by 258
Cellular regulation of islet hormone secretion by the incretin hormone glucagon-like peptide 1
Gromada, J., Holst, J. J., & Rorsman, P. (1998) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s004240050558 · Cited by 254
Self-citationGreenfield, J. R., Farooqi, I. S., Keogh, J. M., Henning, E., Habib, A. M., Blackwood, A., Reimann, F. M., Holst, J. J., & Gribble, F. M. (2008) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.2008.26362 · Cited by 262
Self-citationHsieh, F.-C., Lee, C.-L., Chai, C., Chen, W., Lu, Y.-C., & Wu, C. (2013) · Nutrition & Metabolism · doi:10.1186/1743-7075-10-35 · Cited by 262
Ma, J., Bellon, M., Wishart, J. M., Young, R. L., Blackshaw, L. A., Jones, K. L., Horowitz, M., & Rayner, C. K. (2009) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.90708.2008 · Cited by 256
MANAGEMENT OF ENDOCRINE DISEASE: Are all GLP-1 agonists equal in the treatment of type 2 diabetes?
Nauck, M. A., & Meier, J. J. (2019) · European Journal of Endocrinology · doi:10.1530/eje-19-0566 · Cited by 254
Self-citationCalanna, S., Christensen, M., Holst, J. J., Laferrère, B., Gluud, L. L., Vilsbøll, T., & Knop, F. K. (2013) · Diabetologia · doi:10.1007/s00125-013-2841-0 · Cited by 251
Self-citationGlucagonlike peptide 1: a newly discovered gastrointestinal hormone
Holst, J. J. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90831-1 · Cited by 252
Self-citationβ Cell tone is defined by proglucagon peptides through cAMP signaling
Capozzi, M. E., Svendsen, B., Encisco, S. E., Lewandowski, S. L., Martin, M. D., Lin, H., Jaffe, J. L., Coch, R. W., Haldeman, J. M., MacDonald, P. E., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.126742 · Cited by 255
Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists
Liu, Q. K. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1431292 · Cited by 265
The incretin system in healthy humans: The role of GIP and GLP-1
Holst, J. J. (2019) · Metabolism · doi:10.1016/j.metabol.2019.04.014 · Cited by 248
Self-citationThe expanding incretin universe: from basic biology to clinical translation
Drucker, D. J., & Holst, J. J. (2023) · Diabetologia · doi:10.1007/s00125-023-05906-7 · Cited by 243
Self-citationWhat do we know about the secretion and degradation of incretin hormones?
Deacon, C. F. (2005) · Regulatory Peptides · doi:10.1016/j.regpep.2004.06.007 · Cited by 244
Nicholls, S. J., Bhatt, D. L., Buse, J. B., Prato, S. D., Kahn, S. E., Lincoff, A. M., McGuire, D. K., Nauck, M. A., Nissen, S. E., Sattar, N., et al. (2024) · American Heart Journal · doi:10.1016/j.ahj.2023.09.007 · Cited by 248
Self-citationAfferent signals regulating food intake
Bray, G. A. (2000) · Proceedings of The Nutrition Society · doi:10.1017/s0029665100000422 · Cited by 241
Killion, E. A., Wang, J., Yie, J., Shi, S. D.-H., Bates, D., Min, X., Komorowski, R., Hager, T., Deng, L., Atangan, L., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aat3392 · Cited by 237
Unimolecular Polypharmacy for Treatment of Diabetes and Obesity
Tschöp, M. H., Finan, B., Clemmensen, C., Gelfanov, V. M., Pérez–Tilve, D., Müller, T. D., & DiMarchi, R. D. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.06.021 · Cited by 236
Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism
Mroz, P. A., Finan, B., Gelfanov, V., Yang, B., Tschöp, M. H., DiMarchi, R. D., & Perez-Tilve, D. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2018.12.001 · Cited by 229
Vilsbøll, T., Knop, F. K., Krarup, T., Johansen, A., Madsbad, S., Larsen, S., Hansen, T. W., Pedersen, O. B., & Holst, J. J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030738 · Cited by 230
Self-citationMeier, J. J., Hücking, K., Holst, J. J., Deacon, C. F., Schmiegel, W., & Nauck, M. A. (2001) · Diabetes · doi:10.2337/diabetes.50.11.2497 · Cited by 233
Self-citationRask, E., Olsson, T., Söderberg, S., Johnson, O., Seckl, J. R., Holst, J. J., & Åhrén, B. (2001) · Diabetes Care · doi:10.2337/diacare.24.9.1640 · Cited by 228
Self-citationGastric Inhibitory Polypeptide: the neglected incretin revisited
Meier, J. J., Nauck, M. A., Schmidt, W. E., & Gallwitz, B. (2002) · Regulatory Peptides · doi:10.1016/s0167-0115(02)00039-3 · Cited by 234
Self-citationGlucagon-like peptide-1: From extract to agent. The Claude Bernard Lecture, 2005
Holst, J. J. (2006) · Diabetologia · doi:10.1007/s00125-005-0107-1 · Cited by 228
Self-citationAlfaris, N., Waldrop, S., Johnson, V., Boaventura, B., Kendrick, K., & Stanford, F. C. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102782 · Cited by 224
Incretin-Based Therapies in Type 2 Diabetes Mellitus
Chia, C. W., & Egan, J. M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2109 · Cited by 223
cAMP signalling in insulin and glucagon secretion
Tengholm, A., & Gylfe, E. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12993 · Cited by 231
Meier, J. J., & Nauck, M. A. (2010) · Diabetes · doi:10.2337/db09-1899 · Cited by 215
Self-citationBalkan, B., Kwasnik, L., Miserendino, R., Holst, J. J., & Li, X. (1999) · Diabetologia · doi:10.1007/s001250051445 · Cited by 213
Self-citationLynn, F. C., Pamir, N., Ng, E. H. C., McIntosh, C. H. S., Kieffer, T. J., & Pederson, R. A. (2001) · Diabetes · doi:10.2337/diabetes.50.5.1004 · Cited by 208
Ritzel, R. A., �rskov, C., Holst, J. J., & Nauck, M. A. (1995) · Diabetologia · doi:10.1007/bf00401846 · Cited by 207
Self-citationDevelopment and Characterization of a Glucagon-Like Peptide 1-Albumin Conjugate
Kim, J., Baggio, L. L., Bridon, D. P., Castaigne, J., Robitaille, M. F., Jetté, L., Benquet, C., & Drucker, D. J. (2003) · Diabetes · doi:10.2337/diabetes.52.3.751 · Cited by 209
The Impact of Diabetes and Diabetes Medications on Bone Health
Gilbert, M. P., & Pratley, R. E. (2015) · Endocrine Reviews · doi:10.1210/er.2012-1042 · Cited by 211
Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes
Drucker, D. (2003) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.12.1.87 · Cited by 237
Gastric Inhibitory Polypeptide and Glucagon-Like Peptide-1 in the Pathogenesis of Type 2 Diabetes
Nauck, M. A., Baller, B., & Meier, J. J. (2004) · Diabetes · doi:10.2337/diabetes.53.suppl_3.s190 · Cited by 163
Self-citationGIP as a Therapeutic Target in Diabetes and Obesity: Insight From Incretin Co-agonists
Holst, J. J., & Rosenkilde, M. M. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa327 · Cited by 207
Self-citationCeriello, A., Novials, A., Ortega, E., Canivell, S., La Sala, L., Pujadas, G., Esposito, K., Giugliano, D., & Genovese, S. (2013) · Diabetes Care · doi:10.2337/dc12-2469 · Cited by 204
Update on cystic fibrosis-related diabetes
Kelly, A. T., & Moran, A. (2013) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2013.02.008 · Cited by 209
Vagal hepatopancreatic reflex effect evoked by intraportal appearance of tGLP-1
Nakabayashi, H., NISHIZAWA, M., Nakagawa, A., Takeda, R., & Niijima, A. (1996) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1996.271.5.e808 · Cited by 203
Brubaker, P. L., & Drucker, D. J. (2002) · Receptors and Channels · doi:10.3109/10606820213687 · Cited by 200
Mentis, N., Vardarli, I., Köthe, L. D., Holst, J. J., Deacon, C. F., Theodorakis, M., Meier, J. J., & Nauck, M. A. (2011) · Diabetes · doi:10.2337/db10-1332 · Cited by 197
Self-citationAnti-obesity therapy: from rainbow pills to polyagonists
Müller, T. D., Clemmensen, C., Finan, B., DiMarchi, R. D., & Tschöp, M. H. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014803 · Cited by 199
Verspohl, E. J. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.06.002 · Cited by 198
Reimer, M. K., Holst, J. J., & Åhrén, B. (2002) · European Journal of Endocrinology · doi:10.1530/eje.0.1460717 · Cited by 196
Self-citationSleeve Gastrectomy With Transit Bipartition
Santoro, S., Castro, L. C., Velhote, M. C. P., Malzoni, C. E., Klajner, S., Castro, L. P., Lacombe, A., & Santo, M. A. (2012) · Annals of Surgery · doi:10.1097/sla.0b013e31825370c0 · Cited by 199
Knop, F. K., Aaboe, K., Vilsbøll, T., Vølund, A., Holst, J. J., Krarup, T., & Madsbad, S. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01549.x · Cited by 196
Self-citationInhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes
Pratley, R. E., & Salsali, A. (2007) · Current Medical Research and Opinion · doi:10.1185/030079906x162746 · Cited by 197
Hvidberg, A., Nielsen, M.-B., Hilsted, J., Ørskov, C., & Holst, J. J. (1994) · Metabolism · doi:10.1016/0026-0495(94)90164-3 · Cited by 195
Self-citationDeacon, C. F., Åhrén, B., & Holst, J. J. (2004) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.13.9.1091 · Cited by 193
Self-citationKnop, F. K., Vilsbøll, T., Madsbad, S., Holst, J. J., & Krarup, T. (2007) · Diabetologia · doi:10.1007/s00125-006-0566-z · Cited by 193
Self-citationIncretin hormones and type 2 diabetes
Nauck, M. A., & Müller, T. D. (2023) · Diabetologia · doi:10.1007/s00125-023-05956-x · Cited by 190
Self-citationHolz, G. G., Leech, C. A., & Habener, J. F. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.30.17749 · Cited by 188
Yabe, D., & Seino, Y. (2011) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2011.07.010 · Cited by 202
Pharmacotherapy of type 2 diabetes: An update
Upadhyay, J., Pοlyzos, S. A., Perakakis, N., Thakkar, B., Paschou, S. Α., Katsiki, N., UNDERWOOD, P. C., Park, K., Seufert, J., Kang, E. S., et al. (2017) · Metabolism · doi:10.1016/j.metabol.2017.08.010 · Cited by 196
Eguchi, Y., Kitajima, Y., Hyogo, H., Takahashi, H., Kojima, M., Ono, M., Araki, N., Tanaka, K., Yamaguchi, M., Matsuda, Y., et al. (2015) · Hepatology Research · doi:10.1111/hepr.12351 · Cited by 182
Intestinal Cholecystokinin Controls Glucose Production through a Neuronal Network
Cheung, G. W. C., Kokorovic, A., Lam, C., Chari, M., & Lam, T. K. T. (2009) · Cell Metabolism · doi:10.1016/j.cmet.2009.07.005 · Cited by 188
Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes
Gautier, J. F., Choukem, S. P., & Girard, J. R. (2008) · Diabetes & Metabolism · doi:10.1016/s1262-3636(08)73397-4 · Cited by 186
Jensen, C. B., Storgaard, H., Dela, F., Holst, J. J., Madsbad, S., & Vaag, A. A. (2002) · Diabetes · doi:10.2337/diabetes.51.4.1271 · Cited by 182
Self-citationReappraisal of GIP Pharmacology for Metabolic Diseases
Finan, B., Müller, T. D., Clemmensen, C., Perez-Tilve, D., DiMarchi, R. D., & Tschöp, M. H. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.03.005 · Cited by 180
Glucagon-like peptide 1 and its derivatives in the treatment of diabetes
Nauck, M. A., & Meier, J. J. (2004) · Regulatory Peptides · doi:10.1016/j.regpep.2004.07.014 · Cited by 179
Self-citationMabilleau, G., Mieczkowska, A., & Chappard, D. (2014) · Journal of Diabetes · doi:10.1111/1753-0407.12102 · Cited by 178
Nauck, M. A., Vilsbøll, T., Gallwitz, B., Garber, A. J., & Madsbad, S. (2009) · Diabetes Care · doi:10.2337/dc09-s315 · Cited by 182
Self-citationKendall, D. M., Cuddihy, R. M., & Bergenstal, R. M. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.03.015 · Cited by 177
Rocca, A. S., LaGreca, J., Kalitsky, J., & Brubaker, P. L. (2001) · Endocrinology · doi:10.1210/endo.142.3.8034 · Cited by 175
Chia, C. W., Carlson, O. D., Kim, W., Shin, Y., Charles, C., Kim, H. S., Melvin, D. L., & Egan, J. M. (2009) · Diabetes · doi:10.2337/db08-0958 · Cited by 178
Glucagon-Like Peptide-1: Glucose Homeostasis and Beyond
Cho, Y. M., Fujita, Y., & Kieffer, T. J. (2013) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021113-170315 · Cited by 178
Vahl, T. P., Paty, B. W., Fuller, B. D., Prigeon, R. L., & D’Alessio, D. A. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021479 · Cited by 176
Glucagon-like Peptide-1 and the Central/Peripheral Nervous System: Crosstalk in Diabetes
Muscogiuri, G., DeFronzo, R. A., Gastaldelli, A., & Holst, J. J. (2017) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2016.10.001 · Cited by 171
Self-citationRenner, S., Fehlings, C., Herbach, N., Hofmann, A., von Waldthausen, D. C., Keßler, B., Ulrichs, K. F. A., Chodnevskaja, I., Moskalenko, V., Amselgruber, W. M., et al. (2010) · Diabetes · doi:10.2337/db09-0519 · Cited by 172
Glucagon-like peptide-1 can reverse the age-related decline in glucose tolerance in rats.
Wang, Y., Perfetti, R., Greig, N. H., Holloway, H. W., DeOre, K. A., Montrose‐Rafizadeh, C., Elahi, D., & Egan, J. M. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119482 · Cited by 172
Chapter 15 Glucose‐Dependent Insulinotropic Polypeptide (Gastric Inhibitory Polypeptide; GIP)
McIntosh, C. H. S., Widenmaier, S. B., & Kim, S. (2009) · Vitamins and hormones · doi:10.1016/s0083-6729(08)00615-8 · Cited by 173
Coffee Consumption and Risk of Type 2 Diabetes Mellitus
Pereira, M. A., Parker, E. D., & Folsom, A. R. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.12.1311 · Cited by 173
Important Role of the GLP-1 Axis for Glucose Homeostasis after Bariatric Surgery
Larraufie, P., Roberts, G. P., McGavigan, A. K., Kay, R. G., Li, J., Leiter, A. B., Melvin, A., Biggs, E. K., Ravn, P., Davy, K., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2019.01.047 · Cited by 171
Lund, A., Vilsbøll, T., Bagger, J. I., Holst, J. J., & Knop, F. K. (2011) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00665.2010 · Cited by 175
Self-citationUnraveling the Science of Incretin Biology
Nauck, M. A. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.03.012 · Cited by 168
Self-citationThe development of Byetta (exenatide) from the venom of the Gila monster as an anti-diabetic agent
Furman, B. L. (2012) · Toxicon · doi:10.1016/j.toxicon.2010.12.016 · Cited by 166
BRUBAKER, P. L., Schloos, J., & Drucker, D. J. (1998) · Endocrinology · doi:10.1210/endo.139.10.6228 · Cited by 168
Advances in the Treatment of Type 2 Diabetes Mellitus
Israili, Z. H. (2010) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e3181afbf51 · Cited by 163
Wu, T., Zhao, B. R., Bound, M. J., Checklin, H. L., Bellon, M., Little, T. J., Young, R. L., Jones, K. L., Horowitz, M., & Rayner, C. K. (2012) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.111.021543 · Cited by 163
Gautier, J. F., Fetita, S., Sobngwi, E., & Salaun-Martin, C. (2005) · Diabetes & Metabolism · doi:10.1016/s1262-3636(07)70190-8 · Cited by 164
Metadata
- Authors
- Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W.
- Affiliations
- University of Göttingen (DE)
- University of Copenhagen (DK)
- Rigshospitalet (DK)
- Venue
- Journal of Clinical Investigation
- Published
- 1993-01-01
- Volume
- 91
- Issue
- 1
- Pages
- 301-307
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC330027
- OpenAlex
- W1969932276
- Cited by
- 1,651
- References
- 41
- Citations by year
- 2026: 45 · 2025: 51 · 2024: 63 · 2023: 63 · 2022: 57 · 2021: 57 · 2020: 50 · 2019: 70 · 2018: 50 · 2017: 49 · 2016: 71 · 2015: 62 · 2014: 75 · 2013: 84 · 2012: 59
- FWCI
- 16.84
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- Deutsche Forschungsgemeinschaft (203/2-1)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- glucagon-like peptide-1, GLP-1(7-36)amide, glucose-dependent insulinotropic polypeptide, type 2 diabetes, insulin secretion, C-peptide, glucagon, hyperglycemic clamp, incretin resistance
- MeSH terms
- Insulin Secretion, Blood Glucose, C-Peptide, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Female, Gastric Inhibitory Polypeptide, Glucagon, Glycated Hemoglobin, Humans, Insulin, Kinetics, Male, Middle Aged, Peptide Fragments, Protein Precursors, Reference Values, Time Factors, Glucose Clamp Technique, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
